tiprankstipranks
Cytokinetics (CYTK)
NASDAQ:CYTK
US Market

Cytokinetics Income Statement

Last quarter (Q3 2024), Cytokinetics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Cytokinetics's net income was $-160.54M. See Cytokinetics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ -322.59M$ -146.22M$ -89.51M$ -41.12M$ 26.87M
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 11.90M$ 5.80M$ 2.30M$ 1.80M$ 1.30M
EBITDA
$ -456.68M$ -331.99M$ -183.71M$ -86.78M$ -95.63M
Operating Income
$ -496.20M$ -324.20M$ -186.31M$ -93.94M$ -98.87M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -526.24M$ -388.95M$ -215.31M$ -127.29M$ -121.69M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Cytokinetics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis